Comments
Natco Pharma’s consolidated net profit increased 83 per cent in the second quarter ended September 30, 2024, at ₹676.5 crore as against ₹369 crore in the corresponding quarter of the previous fiscal.
The total revenue of the Hyderabad-based company grew 35 per cent at ₹1,435 crore in the quarter under review (₹1,061 crore).
“The company has shown continued strong growth during the second quarter, driven by exports formulation business and stable domestic pharma business. The Board of Directors has declared a second interim dividend of ₹1.50 per equity share for FY2024-25,’‘ the company said in a release.
Natco Pharma’s scrip remained flat on Tuesday to end at ₹1,393.15 on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.